Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 17Prostate Cancer Metastatic 3Neoplasms 3Stomach Neoplasms 2Neoplasm Metastasis 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Metastatic Breast Cancer With Intracranial Metastases 1Malignant Solid Tumor - Malignant Nervous System Neoplasm 1Lymphadenopathy 1Hormone-Resistant Prostate Cancer 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 43Cyclophosphamide 38fludarabine phosphate 27Cytarabine 26Rituximab 24Methotrexate 21Lenalidomide 21Bortezomib 21Calcium Dobesilate 20fludarabine 19Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 16Mycophenolic Acid 16pembrolizumab 15Gemcitabine 15Etoposide 15pomalidomide 14Melphalan 14Vincristine 13Filgrastim 13Busulfan 13Tacrolimus 12Cyclosporine 12Carboplatin 12Paclitaxel 11carfilzomib 10durvalumab 9Doxorubicin 9Cetuximab 9Brentuximab Vedotin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrence × cabazitaxel × Clear all
NCT01531205 2014-11-05

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
Genitourinary

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡